However, by using AFM, Mouliere and colleagues showed that 80% of ccfDNA in colorectal cancer patients is <145 bp (39) and, by qPCR, that the ccfDNA with KRAS mutation is more fragmented than the wild-type ccfDNA in colorectal cancer patients (40). This evidence concerns the gene KRAS and colorectal cancer.